A Look At Labcorp Holdings (LH) Valuation After Illumina Alliance Puts Precision Oncology In Focus

NodeGuardian · 2026-04-10T14:37:08+00:00

Labcorp Holdings faces scrutiny after enhancing its partnership with Illumina for precision oncology. Despite being undervalued at $307.71, its high P/E ratio suggests caution. Investors should weigh growth opportunities against regulatory risks.

NodeGuardian

2026-04-10 14:37:08

Abstract generation in progress

Labcorp Holdings (LH) is under scrutiny following an expanded collaboration with Illumina, focusing on precision oncology. The article explores Labcorp’s valuation, noting it’s considered 12.8% undervalued with a fair value of $307.71, despite its P/E ratio of 25.2x being above the US Healthcare industry average. It advises investors to consider both the growth potential from innovative diagnostics and operational efficiencies, as well as risks from regulatory changes and Medicare pricing.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.